Michigan State University

Vanderbilt University

Caryl E Sortwell

Jack W Lipton

Nicholas Kanaan

Mallory Hacker

David Charles

Timothy Collier

Fredric P Manfredsson

Kathy Steece-Collier

Provided herein are methods and compositions for determining the susceptibility of Parkinson's disease patients to optimized drug therapy (ODT) and or deep brain stimulation (DBS) therapy.

Predicting therapeutic response in Parkinson's disease

Methods of treating movement disorders by reducing the activity of Nurr1 are disclosed. These methods are particularly applicable to subjects suffering from Parkinson's disease who have either developed levodopa-induced dyskinesia (LID) or are at risk of developing LID. In some aspects, the invention relates to a method for treating a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, wherein said composition reduces the activity of a nuclea receptor related 1 protein ('Nurr1'). In some embodiments, the movement disorder is a dyskinesia. The movement disorder may be a levodopa-induced dyskinesia.

Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease

Growing community of inventors

Grand Rapids, MI, United States of America

Caryl E Sortwell